Full Text:   <2506>

CLC number: R735.3

On-line Access: 

Received: 2005-09-15

Revision Accepted: 2005-11-15

Crosschecked: 0000-00-00

Cited: 18

Clicked: 5863

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2006 Vol.7 No.3 P.235-240

http://doi.org/10.1631/jzus.2006.B0235


Preoperatively molecular staging with CM10 ProteinChip and SELDI-TOF-MS for colorectal cancer patients


Author(s):  Xu Wen-Hong, Chen Yi-Ding, Hu Yue, Yu Jie-Kai, Wu Xian-Guo, Jiang Tie-Jun, Zheng Shu, Zhang Su-Zhan

Affiliation(s):  Cancer Institute, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; more

Corresponding email(s):   zhangscy@tom.com

Key Words:  Colorectal cancer, SELDI-TOF-MS (surface enhanced laser desorption/ionization-time of flight-mass spectrometry), Staging, Bio-informatics


Xu Wen-Hong, Chen Yi-Ding, Hu Yue, Yu Jie-Kai, Wu Xian-Guo, Jiang Tie-Jun, Zheng Shu, Zhang Su-Zhan. Preoperatively molecular staging with CM10 ProteinChip and SELDI-TOF-MS for colorectal cancer patients[J]. Journal of Zhejiang University Science B, 2006, 7(3): 235-240.

@article{title="Preoperatively molecular staging with CM10 ProteinChip and SELDI-TOF-MS for colorectal cancer patients",
author="Xu Wen-Hong, Chen Yi-Ding, Hu Yue, Yu Jie-Kai, Wu Xian-Guo, Jiang Tie-Jun, Zheng Shu, Zhang Su-Zhan",
journal="Journal of Zhejiang University Science B",
volume="7",
number="3",
pages="235-240",
year="2006",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2006.B0235"
}

%0 Journal Article
%T Preoperatively molecular staging with CM10 ProteinChip and SELDI-TOF-MS for colorectal cancer patients
%A Xu Wen-Hong
%A Chen Yi-Ding
%A Hu Yue
%A Yu Jie-Kai
%A Wu Xian-Guo
%A Jiang Tie-Jun
%A Zheng Shu
%A Zhang Su-Zhan
%J Journal of Zhejiang University SCIENCE B
%V 7
%N 3
%P 235-240
%@ 1673-1581
%D 2006
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2006.B0235

TY - JOUR
T1 - Preoperatively molecular staging with CM10 ProteinChip and SELDI-TOF-MS for colorectal cancer patients
A1 - Xu Wen-Hong
A1 - Chen Yi-Ding
A1 - Hu Yue
A1 - Yu Jie-Kai
A1 - Wu Xian-Guo
A1 - Jiang Tie-Jun
A1 - Zheng Shu
A1 - Zhang Su-Zhan
J0 - Journal of Zhejiang University Science B
VL - 7
IS - 3
SP - 235
EP - 240
%@ 1673-1581
Y1 - 2006
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2006.B0235


Abstract: 
Objectives: To detect the serum proteomic patterns by using SELDI-TOF-MS (surface enhanced laser desorption/ ionization-time of flight-mass spectrometry) technology and CM10 ProteinChip in colorectal cancer (CRC) patients, and to evaluate the significance of the proteomic patterns in the tumour staging of colorectal cancer. Methods: SELDI-TOF-MS and CM10 ProteinChip were used to detect the serum proteomic patterns of 76 patients with colorectal cancer, among them, 10 Stage I, 19 Stage II, 16 Stage III and 31 Stage IV samples. Different stage models were developed and validated by support vector machines, discriminant analysis and time-sequence analysis. Results: The Model I formed by 6 protein peaks (m/z: 2759.58, 2964.66, 2048.01, 4795.90, 4139.77 and 37761.60) could be used to distinguish local CRC patients (Stage I and Stage II) from regional CRC patients (Stage III) with an accuracy of 86.67% (39/45). The Model II formed by 3 protein peaks (m/z: 6885.30, 2058.32 and 8567.75) could be used to distinguish locoregional CRC patients (Stage I, Stage II and Stage III) from systematic CRC patients (Stage IV) with an accuracy of 75.00% (57/76). The Model III could distinguish Stage I from Stage II with an accuracy of 86.21% (25/29). The Model IV could distinguish Stage I from Stage III with accuracy of 84.62% (22/26). The Model V could distinguish Stage II from Stage III with accuracy of 85.71% (30/35). The Model VI could distinguish Stage II from Stage IV with accuracy of 80.00% (40/50). The Model VII could distinguish Stage III from Stage IV with accuracy of 78.72% (37/47). Different stage groups could be distinguished by the two-dimensional scattered spots figure obviously. Conclusion: This method showed great success in preoperatively determining the colorectal cancer stage of patients.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Alexe, G., Alexe, S., Liotta, L.A., Petricoin, E., Reiss, M., Hammer, P.L., 2004. Ovarian cancer detection by logical analysis of proteomic data. Proteomics, 4(3):766-783.

[2] Chen, Y.D., Zheng, S., Yu, J.K., Hu, X., 2004. Development of serum biomarker model and its application in colorectal cancer diagnosis. J. Tumor. Marker Oncol., 19(3):251-258.

[3] Greenlee, R.T., Murray, T., Bolden, S., Wingo, P.A., 2000. Cancer statistics 2000. CA Cancer J. Clin., 50(1):7-33.

[4] Harris, G.J., Church, J.M., Senagore, A.J., Lavery, I.C., Hull, T.L., Strong, S.A., Fazio, V.W., 2002. Factors affecting local recurrence of colonic adenocarcinoma. Dis. Colon Rectum, 45(8):1029-1034.

[5] Hawk, E.T., Levin, B., 2005. Colorectal cancer prevention. J. Clin. Oncol., 23(2):378-391.

[6] Issaq, H.J., Veenstra, T.D., Conrads, T.P., Felschow, D., 2002. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun., 292(3):587-592.

[7] Kotake, K., Koyama, Y., 1995. Neoadjuvant therapy for colorectal cancer. Gan. to Kagaku Ryoho, 22(13):1886-1892.

[8] Merchant, M., Weinberger, S.R., 2000. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis, 21(6):1164-1177.

[9] Paradis, V., Degos, F., Dargere, D., Pham, N., Belghiti, J., Degott, C., Janeau, J.L., Bezeaud, A., Delforge, D., Cubizolles, M., et al., 2005. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology, 41(1):40-47.

[10] Ries, L.A., Wingo, P.A., Miller, D.S., Howe, H.L., Weir, H.K., Rosenberg, H.M., Vernon, S.W., Cronin, K., Edwards, B.K., 2000. The annual report to the nation on the status of cancer, 1973~1997, with a special section on colorectal cancer. Cancer, 88(10):2398-2424.

[11] Semmes, O.J., Feng, Z., Adam, B.L., Banez, L.L., Bigbee, W.L., Campos, D., Cazares, L.H., Chan, D.W., Grizzle, W.E., Izbicka, E., et al., 2005. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem., 51(1):102-112.

[12] Weinberger, S.R., Morris, T.S., Pawlak, M., 2000. Recent trends in protein biochip technology. Pharmacogenomics, 1(4):395-416.

[13] Zheng, S., Cai, S.R., 2003. Colorectal cancer epidemiology and prevention study in China. Chinese-German J. Clin. Oncol., 2(2):72-75.

[14] Zhukov, T.A., Johanson, R.A., Cantor, A.B., Clark, R.A., Tockman, M.S., 2003. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer, 40(3):267-279.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE